Operator
Good afternoon, ladies and gentlemen, and welcome to the Santhera Pharmaceuticals Half Year Results Investor Presentation. [Operator Instructions] Before we begin, we would like to submit the following poll. And if you could give that your kind attention, I’m sure the company would be most grateful. And I would now like to hand you over to the team from Santhera Pharmaceuticals, Catherine and Shabir. Good afternoon.
Catherine Isted
Chief Financial Officer
Good afternoon, everyone, and welcome again to the interim results for the 6 months ending the 30th of June 2025. Giving the presentation today is myself, Catherine Isted, the CFO; as well as our Chief Medical Officer, Dr. Shabir Hasham. Unfortunately, our CEO, Dario Eklund, cannot be with us today as he’s actually had a recent operation on his shoulder, but he will be back with us shortly. As was said in the introduction, there will be an opportunity to ask questions at the end of the presentation. So please add these into the box as we go along.
To start with, as always, we have the disclaimer. Please feel free to read this at your leisure. While I appreciate this is a results call, we thought it’s worthwhile spending a bit of time going through who Santhera is and what we do and also a reminder about the DMD market. So I will start off with this small snapshot of the company.
So we are a Swiss listed company, listed on SIX with our global headquarters in Basel, with about 110 employees, in total about 150, including contractors. We have a product called AGAMREE. This is a differentiated product in the Duchenne muscular
Read the full article here
